HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company…
Read More...
Read More...
Browsing Tag
#hillevax
HilleVax Announces Results from 5-Year Clinical Study Supporting Long-Term Immunogenicity of HIL-214…
Pan-Ig and HBGA blocking antibody responses persisted to year 5 No adverse events deemed related to HIL-214…
Read More...
Read More...
HilleVax Announces Initiation of Phase 2b Clinical Trial of HIL-214 Vaccine Candidate for the…
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a biopharmaceutical company focused on the…
Read More...
Read More...
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop…
Dubai, United Arab Emirates, July 30, 2021 (GLOBE NEWSWIRE) -- Takeda Pharmaceutical Company Limited…
Read More...
Read More...